Skip to main content

Table 4 Demographic characteristics of all studied subjects and statistical comparison between the various studied parameters in HCC patients versus healthy ccontrol and HCV patientsab

From: CTNNB1 polymorphism (rs121913407) in circulating tumor DNA (ctDNA) in Egyptian hepatocellular carcinoma patients

Parameters

Healthy control (n = 10)

HCV patients (n = 10)

HCC patients (n = 28)

p-value HCC vs healthy control

p-value HCC vs HCV

Gender

 Female n (%)

1 (10)

1 (10)

3 (10.7)

0.950b

0.095b

 Male n (%)

9 (90)

9 (90)

25 (89.3)

  

Age (years)

60.5 (56.5–62)

64 (60–69.3)

60 (58–63.7)

0.950a

0.075a

AST (U/L)

12.5 (11.75–18.25)

24.0 (18.7–35.2)

50.5 (35–107)

< 0.0001a

0.001a

ALT (U/L)

17.0 (12.50–21.25)

24.0 (12.0–51.7)

47.5 (27.75–63.60)

0.0002a

0.0414a

INR

0.85 (0.61–1.10)

1.04 (1.0–1.29)

1.20 (1.10–1.39)

< 0.0001a

0.0158a

Albumin (g/dl)

3.90 (3.15–4.60)

3.90 (3.30–4.65)

3.35 (2.62–3.60)

0.0018a

0.104a

Total bilirubin (mg/dl)

0.40 (0.20–0.85)

0.50 (0.27–0.92)

1.30 (0.90–2.30)

< 0.0001a

0.0002a

BUN (mg/dl)

17.5 (9.2–20.2)

20.5 (17.0–24.0)

20.0 (12.0–32.0)

0.2801a

0.8941a

Creatinine (mg/dl)

0.90 (0.70–1.03)

0.95 (0.77–1.12)

0.95 (0.80–1.20)

0.4487a

0.752a

  1. AFP alpha‑fetoprotein, ALT alanine aminotransferase, AST aspartate aminotransferase, BUN blood urea nitrogen, HCC hepatocellular carcinoma, INR international normalized ratio. Data are presented as median (interquartile range) or number (%). < 0.05 is significant
  2. aStatistical comparison using Wilcoxon’s rank-sum test
  3. bStatistical comparison using chi-square test